An observational study in Diabetes Type 2 and Diabetes Type 1, sponsored by Henrik Bo Wiberg Larsson. Recruiting at 3 sites in 2 countries. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Henrik Bo Wiberg Larsson · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark — 44 open to participants now, 62 under way, 8 of them phase 3. Diabetes Mellitus, Type 2 · Denmark.
Among the 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark, this one is the 49th largest by planned enrollment of the 97 observational ones that give a count, is one of 23 that started in 2026, is one of 97 observational ones, reaches primary completion later than 61 of the 61 other live ones, and was the 457th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →44 of the 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
AstraZeneca · Sites in Denmark, United States, Argentina and 8 more countries
Ages 18+
AstraZeneca · Sites in Denmark, United States, Argentina and 10 more countries
Ages 18+
AstraZeneca · Sites in Denmark, United States, Argentina and 21 more countries
Ages 18+
AstraZeneca · Sites in Denmark, United States, Bulgaria and 13 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
478 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 51 · Phase 3 89 · Phase 4 49
First in 1992; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 64 across the 380 interventional studies, 150 across the 97 observational. Of the 371 that completed or were terminated, 82 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 478 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Henrik Bo Wiberg Larsson as lead sponsor.
Henrik Bo Wiberg Larsson has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
14 of the studies in Diabetes Mellitus, Type 2 with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482072Rigshospitalet, DenmarkBrain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study | 2026-12 |
| NCT07421024Morten Hostrup, PhDGRK-Biased Activation Via β2-Adrenergic Receptors in Human Skeletal Muscle | 2026-12-31 |
| NCT03620266Ole Frobert, MD, PhDEffects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI | 2026-12-31 |
| NCT05915260Slagelse HospitalCMR in T2DM: The NSR Cohort | 2026-12-31 |
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with diabetes are at increased risk of developing dementia, including Alzheimer's disease and vascular dementia. In addition, persons with diabetes have more pronounced age-related brain atrophy and cognitive difficulties compared to people without diabetes. The mechanisms behind the effects on the brain of diabetes are still unclear. New research suggests that the brains of some people with diabetes do not respond normally to insulin signals, a condition known as brain insulin resistance (BIR). To date, there have been no large clinical studies investigating BIR and its impact on brain health, but several smaller studies suggest that BIR may be a cause of cognitive decline and impaired brain health in people with diabetes. Another mechanism that may contribute to impaired brain health in people with diabetes is damage to the blood vessels in the brain. Damage to blood vessels is a well-known complication of diabetes, but how it affects the brain is not fully described. In this project, we will investigate the relationship between BIR and brain blood vessel dysfunction and its relationship to cognition and brain function. This is done by examining patients with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy controls. The participants will undergo MRI brain scans to assess the impact of BIR on the brain physiology and to evaluate brain blood vessel health. Participants will undergo comprehensive assessments of their cognitive abilities and thorough health examination.
The BIR-BrainHealth project investigates the role of brain insulin resistance (BIR) as a key mechanism linking diabetes to cognitive decline and dementia risk. By combining cognitive testing with advanced neuroimaging (MRI and PET), metabolic profiling, and multi-omics analyses, the study aims to uncover how BIR affects brain physiology, energy metabolism, and neurovascular function. The present trial registration specifically covers the MRI components of the project and does not include PET imaging.
Diabetes significantly increases the risk of mild cognitive impairment and dementia. The exact link between diabetes and cognitive decline is yet to be fully understood. Early cognitive decline in diabetes suggests a unique pathogenetic trajectory. One hypothesized mechanism involves impaired insulin signaling/transport in the brain, referred to as brain insulin resistance (BIR). Evidence indicates that in some individuals with diabetes, neuronal insulin signaling is abnormal, resulting in dysregulated cerebral metabolism and function. Another possible pathway is cerebrovascular pathology, which may compromise cerebral perfusion and energy metabolism. The present project will investigate the relationship between BIR and cerebrovascular dysfunction, and their impact on cognition and brain function.
We will set up a multicenter study in Denmark and Germany. Initially the study will include 50 participants with type 1 diabetes, 50 participants with type 2 diabetes, and 50 control participants without diabetes. All participants will undergo a comprehensive clinical evaluation to characterize diabetes duration, severity, and systemic comorbidities. The cognitive performance of the participants will be assessed using a neuropsychological test battery of following standardized tests:
Tests will be grouped by cognitive domains, and each domain score is calculated as the mean of the individual component z-scores. A cognitive composite (global score) will be derived from the mean of the domains: learning and memory, executive function and working memory, processing speed, and attention.
Magnetic resonance imaging (MRI) will be performed to assess BIR and structural brain changes, including atrophy. All MRI-scans will be performed on a research-optimized 3 Tesla MRI scanner. BIR will be evaluated by measuring changes in cerebral perfusion from administration of intranasal insulin delivered via nasal spray.
Blood, urine and stool will be collected for biomarker development and characterization of patients with BIR. A multi-omics approach will be applied to identify reliable biomarkers of BIR, incorporating lipidomics, metabolomics, proteomics, and transcriptomics. Lipidomic analysis will quantify approximately 650 lipid species, including phospholipids, lysophos-pholipids, ceramides, sphingolipids, diacylglycerols, and triacylglycerols, using liquid chromatography-mass spectrometry. Metabolomic profiling will measure approximately 300 metabolites, including citric acid cycle intermediates, short-chain fatty acids, ketones, and amino acids, using gas chromatography-mass spectrometry. Proteomic analysis will be conducted using a validated, clinically applicable mass spectrometry method, and transcriptomic profiling will be performed using RNA-based methods. The participants will be genotyped using the Illumina Infinium Global Screening Array (GSA v2.4), with exclusion of rare variants and clinically relevant mutations listed by the American College of Medical Genetics, in accordance with the guidelines of the National Science Ethics Committee on genomic research.
A subset of participants will undergo additional advanced MRI-scanning for assessments of cerebro-vascular function. Brain perfusion, blood-brain barrier integrity, and capillary perfusion distribution will be measured using dynamic contrast-enhanced MRI. Cerebrovascular reactivity will be measured by perfusion-weighted MRI during inhalation of air enriched with 5% CO2, a potent cerebral vasodilator. Cerebral blood flow responses to neuronal activation induced by visual stimulation will be assessed using perfusion-weighted MRI. Lastly, in a subset of participants the brain glucose sensing will be assessed using functional MRI (fMRI). fMRI will be measured prior to, during and following oral ingestion of water containing 75 grams of glucose. The glucose drink is given through a straw while the participants are lying in the scanner and will be consumed over a period of 5 minutes. Blood samples will be collected throughout the scan for measurements of blood glucose.
It is planned to recruit participants in the Greater Copenhagen area in Denmark and the Ulm area in Germany. The participants will be recruited from the outpatient clinic at Steno Diabetes Center Copenhagen and Ulm University Hospital and primary care settings in Denmark and Germany.
In addition to this, participants will be sought by physical advertisements in the local area, through recruitment platforms (join.trialtree.com) and social media.
Inclusion Criteria (all):
Inclusion Criteria (diabetes only):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals who have a type 1 diabetes diagnose and meet the inclusion and exclusion criteria.
Individuals who have a type 2 diabetes diagnose and meet the inclusion and exclusion criteria.
Individuals who do not have a diabetes diagnose and meet the inclusion and exclusion criteria.
Correlation between brain insulin response and cognitive measures
Brain insulin response is assessed by measuring changes in cerebral blood flow following intranasal insulin administration, using arterial spin labelling (ASL) MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
Correlation between cerebrovascular reactivity and cognitive measures
Cerebrovascular reactivity is assessed by measuring changes in cerebral blood flow responses to inhalation of hypercapnic air (air enriched with 5% CO2). Cerebral blood flow is measured using combined blood-oxygen-level-dependent (BOLD) MRI, ASL MRI, and phase contrast mapping (PCM) MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
Blood-brain-barrier permability
Differences in blood-brain-barrier permeability between groups, measured by dynamic contrast enhanced MRI.
Time frame: Baseline (only measured once)
Neurovascular coupling
Differences in cerebral blood flow responses to visual stimulation between groups, assessed with ASL MRI.
Time frame: Baseline (only measured once)
Hypothalamic glucose sensing
Differences in cerebral blood flow response in the hypothalamus to glucose ingestion between groups, assessed by combined BOLD and ASL MRI.
Time frame: Baseline (only measured once)
Brain insulin response
Differences in brain insulin response between groups, assessed by measuring changes in cerebral blood flow following intranasal insulin administration using ASL MRI.
Time frame: Baseline (only measured once)
Cerebrovascular reactivity
Differences in cerebrovascular reactivity between groups, assessed by measuring changes in cerebral blood flow in response to inhalation of hypercapnic air (air enriched with 5% CO2). Cerebral blood flow is measured using combined blood-oxygen-level-dependent (BOLD) MRI, ASL MRI, and phase contrast mapping (PCM) MRI.
Time frame: Baseline (only measured once)
Brain atrophy and white matter lesion
Differences in brain atrophy and white matter lesion load between groups, assessed by T1- weighted structural MRI and Fluid-Attenuated Inversion Recovery (FLAIR) MRI.
Time frame: Baseline (only measured once)
Correlation between brain atrophy and white matter lesions load and cognitive measures
Brain atrophy and white matter lesion load is assessed by T1- weighted structural MRI and FLAIR MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
Cerebral microbleeds
Differences in the amount of cerebral microbleeds between groups, assessed by susceptibility-weighted MRI.
Time frame: Baseline (only measured once)
Correlation between cerebral microbleeds and cognitive measures
Cerebral microbleeds is assessed by susceptibility-weighted MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
Structural connectivity
Differences in structural connectivity between groups, assessed by diffusion tensor imaging (DTI) MRI.
Time frame: Baseline (only measured once)
Correlation between structural connectivity and cognitive measures
Structural connectivity is assessed by DTI MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
White matter diffusion integrity
Differences in white matter diffusion parameters between groups, assessed by DTI MRI.
Time frame: Baseline (only measured once)
Correlation between white matter diffusion integrity and cognitive measures
White matter diffusion is assessed by DTI MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once
Cerebral blood flow
Differences in resting cerebral blood flow between groups, assessed by ASL and PCM MRI.
Time frame: Baseline (only measured once)
Correlation between resting cerebral blood flow and cognitive measures
Resting cerebral blood flow is assessed by ASL and PCM MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
Cerebral metabolic rate of oxygen
Differences in resting cerebral metabolic rate of oxygen between groups, assessed by combined PCM MRI and susceptibility-based oximetry (SBO) MRI.
Time frame: Baseline (only measured once)
Correlation between cerebral metabolic rate of oxygen and cognitive measures
Cerebral metabolic rate of oxygen is assessed by combined PCM MRI and SBO MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
Regional brain glucose sensing
Differences in regional cerebral blood flow in response to glucose ingestion between groups, assessed by combined BOLD and ASL MRI.
Time frame: Baseline (only measured once)
Correlation between hypothalamic glucose sensing and biomarkers
Cerebral blood flow response in the hypothalamus to glucose ingestion is assessed by combined BOLD and ASL MRI. A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify reliable biomarkers of brain insulin sensing.
Time frame: Baseline (only measured once)
Correlation between brain insulin response and hypothalamic glucose sensing
Brain insulin response is assessed by measuring changes in cerebral blood flow following administration of intranasal insulin using arterial spin labelling ASL MRI. Cerebral blood flow response in the hypothalamus to glucose ingestion is measured by combined BOLD and ASL MRI.
Time frame: Baseline (only measured once)
Biomarkers of neuronal damage, neuroinflammation, and brain insulin response
Brain insulin response is assessed by measuring changes in cerebral blood flow following administration of intranasal insulin using ASL MRI. A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify biomarkers of neuronal damage, neuroinflammation and brain insulin resistance.
Time frame: Baseline (only measured once)
Biomarkers of blood-brain-barrier integrity and cerebrovascular function
Blood-brain-barrier permeability is assessed by dynamic contrast enhanced MRI A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify biomarkers of vascular function and blood brain barrier integrity.
Time frame: Baseline (only measured once)
Correlation between biomarkers and cognitive measures
A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify biomarkers of cognition. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)
Time frame: Baseline (only measured once)
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Oct 2031, 69 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.